For the third quarter of 2026, analysts expect Surrozen Inc to report a consensus revenue of $0.48 million and a loss per share of $1.32, while the stock currently trades around $30.12, well below the average analyst price target of $47.50.
Investors are primarily focused on the company's clinical pipeline progression, specifically the initiation of the DUET Phase 1b/2a study for its lead candidate, SZN-8141, in diabetic macular edema.
Surrozen recently reached a significant milestone by receiving FDA IND clearance for SZN-8141 and successfully secured $95 million in financing to extend its cash runway into 2027.
Despite heavy R&D spending leading to a quarterly net loss, the market remains optimistic about the company’s proprietary Wnt-modulating platform and its potential to address sight-threatening ophthalmic conditions.